NEW YORK, March 03, 2018 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (NASDAQ:SGYP) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of New York, and Docketed under 18-cv-00873, is on behalf of a class consisting of investors who purchased or otherwise acquired Synergy securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Synergy securities between September 5, 2017 and November 14, 2017, both dates inclusive, you have until April 10, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Synergy is a biopharmaceutical company focused on development and commercialization of therapies to treat Gastro-Intestinal disorders and diseases. Throughout the Class Period, Synergy had only one FDA-approved commercial product, TRULANCE (plecanatide) (“Trulance”), a drug for the once-daily treatment of chronic idiopathic constipation (“CIC”). Trulance was approved by the FDA on January 19, 2017 and became available for purchase at the end of the first quarter of 2017. on September 5, 2017, the beginning of the Class Period, Synergy announced that it closed on a $300 million …
The post SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP appeared first on MrTopStep.com.